Literature DB >> 12209491

Guidelines for immunologic laboratory testing in the rheumatic diseases: an introduction.

.   

Abstract

Entities:  

Mesh:

Year:  2002        PMID: 12209491     DOI: 10.1002/art.10381

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


× No keyword cloud information.
  9 in total

1.  Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.

Authors:  T Kaiser; J Langhorst; H Wittkowski; K Becker; A W Friedrich; A Rueffer; G J Dobos; J Roth; D Foell
Journal:  Gut       Date:  2007-08-03       Impact factor: 23.059

2.  S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin.

Authors:  Helmut Wittkowski; Michael Frosch; Nico Wulffraat; Raphaela Goldbach-Mansky; Tilmann Kallinich; Jasmin Kuemmerle-Deschner; Michael C Frühwald; Sandra Dassmann; Tuyet-Hang Pham; Johannes Roth; Dirk Foell
Journal:  Arthritis Rheum       Date:  2008-12

Review 3.  Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies.

Authors:  Michael Mahler; Pier-Luigi Meroni; Xavier Bossuyt; Marvin J Fritzler
Journal:  J Immunol Res       Date:  2014-04-27       Impact factor: 4.818

Review 4.  Laboratory evaluation in rheumatic diseases.

Authors:  Murat Birtane; Selçuk Yavuz; Nurettin Taştekin
Journal:  World J Methodol       Date:  2017-03-26

5.  Pattern of antinuclear antibody and antiextractable nuclear antigen antibody test requisitions in Riyadh.

Authors:  Najla Ali Alghabban; Zahid Shakoor
Journal:  J Family Med Prim Care       Date:  2019-11-15

6.  Clinical utility of ANA-ELISA vs ANA-immunofluorescence in connective tissue diseases.

Authors:  Omar Suhail Alsaed; Laith Ishaq Alamlih; Omar Al-Radideh; Prem Chandra; Samar Alemadi; Abdul-Wahab Al-Allaf
Journal:  Sci Rep       Date:  2021-04-15       Impact factor: 4.379

Review 7.  Attending to warning signs of primary immunodeficiency diseases across the range of clinical practice.

Authors:  Beatriz Tavares Costa-Carvalho; Anete Sevciovic Grumach; José Luis Franco; Francisco Javier Espinosa-Rosales; Lily E Leiva; Alejandra King; Oscar Porras; Liliana Bezrodnik; Mathias Oleastro; Ricardo U Sorensen; Antonio Condino-Neto
Journal:  J Clin Immunol       Date:  2013-11-16       Impact factor: 8.317

8.  What does it mean if a patient is positive for anti-Jo-1 in routine hospital practice? A retrospective nested case-control study.

Authors:  Paresh Jobanputra; Feryal Malick; Emma Derrett-Smith; Tim Plant; Alex Richter
Journal:  F1000Res       Date:  2018-06-04

Review 9.  The Past, Present, and Future in Antinuclear Antibodies (ANA).

Authors:  Juan Irure-Ventura; Marcos López-Hoyos
Journal:  Diagnostics (Basel)       Date:  2022-03-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.